ANKE BIO(SZ:300009) Zhong Guo Zheng Quan Bao·2025-11-11 14:06Core Viewpoint - Anke Bio has entered into a strategic partnership with Boshengji Pharmaceutical Technology, marking a significant upgrade from previous collaborations to a comprehensive partnership involving capital investment and commercial operations [1][4]. Group 1: Investment and Partnership Details - Anke Bio will invest an additional 30 million yuan in Boshengji, becoming the second-largest shareholder [1][4]. - The partnership includes exclusive agency rights for Anke Bio to market Boshengji's core product, PA3-17 injection, nationwide [1][3]. Group 2: Product and Clinical Development - The collaboration focuses on PA3-17 injection, the world's first targeted CD7 CAR-T cell therapy product approved for clinical trials, developed by Boshengji's subsidiary [3][4]. - PA3-17 injection has shown promising safety and efficacy in Phase I clinical trials for patients with relapsed/refractory T-ALL and T-LBL [3][4]. - The product is included in the National Medical Products Administration's list of breakthrough therapies and is entering the critical Phase II clinical trial stage [3][4]. Group 3: Strategic Implications - The agreement extends beyond PA3-17 injection, granting Anke Bio priority agency rights for future innovative products from Boshengji [4]. - Anke Bio's established marketing system and commercial experience are expected to facilitate rapid market penetration for PA3-17 injection [4]. - This dual approach of "capital investment + exclusive agency" is seen as a strategic move to accelerate the commercialization of innovative drugs in the CAR-T therapy sector in China [4].